Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario
Autor(a) principal: | |
---|---|
Data de Publicação: | 2019 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por eng |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/387 |
Resumo: | Cancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients. |
id |
INCA-1_0e1005626ca4dd20391720c950fed416 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/387 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this ScenarioTratamiento de Tromboembolismo Venoso en Pacientes con Cáncer: Actualización sobre el Papel de los Anticoagulantes Orales Directos en este EscenarioTratamento do Tromboembolismo Venoso em Pacientes com Câncer: Atualização quanto ao Papel dos Anticoagulantes Orais Diretos nesse CenárioTromboembolia Venosa/tratamento farmacológicoAnticoagulantesNeoplasiasVenous Thromboembolism/drug therapyAnticoagulantsNeoplasmsTromboembolia Venosa/tratamiento farmacológicoAnticoagulantesNeoplasiasCancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients.El cáncer es ampliamente conocido por aumentar el riesgo de complicaciones tromboembólicas. El riesgo estará relacionado con los factores propios del paciente, sus comorbilidades, factores relacionados con el tumor, el momento del tratamiento y sus condiciones clínicas. La terapia anticoagulante debe prescribirse teniendo en cuenta el riesgo de sangrado y recurrencia de TEV. Con la aparición de nuevos anticoagulantes orales y su uso en pacientes con cáncer asociado a trombosis, se han realizado estudios para validar su uso. Sin embargo, deben considerarse los riesgos para proporcionar la terapia más adecuada y segura. Estas alternativas terapéuticas deben publicarse en los servicios de oncología, facilitando así su uso y mayor beneficio para los pacientes. O câncer é amplamente conhecido por aumentar o risco de complicações tromboembólicas. Esse risco está relacionado às características do próprio paciente, suas comorbidades e condições clínicas, além de fatores relacionados ao tumor e ao momento do tratamento. A terapia anticoagulante deverá ser prescrita levando-se em consideração o risco hemorrágico e de recorrência de trombose venosa profunda (TVP). Estudos clínicos foram realizados para validar a utilização dos novos anticoagulantes orais diretos (DOAC) em pacientes com câncer associado à trombose (CAT). Entretanto, os riscos devem ser considerados com intuito de fornecer a terapia mais adequada e segura para cada paciente. Essas alternativas terapêuticas deverão ser divulgadas nos serviços de oncologia, facilitando assim sua utilização e maior benefício para os pacientes.INCA2019-10-24info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo de opniãoapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/38710.32635/2176-9745.RBC.2019v65n3.387Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-04387Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-04387Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-043872176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/387/478https://rbc.inca.gov.br/index.php/revista/article/view/387/605Copyright (c) 2019 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessRenni, Marcos Jose PereiraMarinho, Tatiana Abelin SaldanhaSouza, Mirian Carvalho de2021-11-29T20:03:43Zoai:rbc.inca.gov.br:article/387Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:03:43Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario Tratamiento de Tromboembolismo Venoso en Pacientes con Cáncer: Actualización sobre el Papel de los Anticoagulantes Orales Directos en este Escenario Tratamento do Tromboembolismo Venoso em Pacientes com Câncer: Atualização quanto ao Papel dos Anticoagulantes Orais Diretos nesse Cenário |
title |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
spellingShingle |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario Renni, Marcos Jose Pereira Tromboembolia Venosa/tratamento farmacológico Anticoagulantes Neoplasias Venous Thromboembolism/drug therapy Anticoagulants Neoplasms Tromboembolia Venosa/tratamiento farmacológico Anticoagulantes Neoplasias |
title_short |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
title_full |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
title_fullStr |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
title_full_unstemmed |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
title_sort |
Venous Thromboembolism Treatment in Cancer Patients: Update of the Role of Direct Oral Anticoagulants in this Scenario |
author |
Renni, Marcos Jose Pereira |
author_facet |
Renni, Marcos Jose Pereira Marinho, Tatiana Abelin Saldanha Souza, Mirian Carvalho de |
author_role |
author |
author2 |
Marinho, Tatiana Abelin Saldanha Souza, Mirian Carvalho de |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Renni, Marcos Jose Pereira Marinho, Tatiana Abelin Saldanha Souza, Mirian Carvalho de |
dc.subject.por.fl_str_mv |
Tromboembolia Venosa/tratamento farmacológico Anticoagulantes Neoplasias Venous Thromboembolism/drug therapy Anticoagulants Neoplasms Tromboembolia Venosa/tratamiento farmacológico Anticoagulantes Neoplasias |
topic |
Tromboembolia Venosa/tratamento farmacológico Anticoagulantes Neoplasias Venous Thromboembolism/drug therapy Anticoagulants Neoplasms Tromboembolia Venosa/tratamiento farmacológico Anticoagulantes Neoplasias |
description |
Cancer is widely known for increasing the risk of thromboembolic complications. The associated risk will be related to the patient's own factors, his/her comorbidities, tumor-related factors, the time of treatment and his/her clinical conditions. Anticoagulant therapy should be prescribed considering the risk of bleeding and VTE recurrence. With the emergence of new oral anticoagulants and their use in patients with thrombosis-associated cancer, studies have been conducted to validate their usage. However, risks should be assessed as to provide the most appropriate and safe therapy. These therapeutic alternatives should be publicized in Oncology services, thus facilitating their usage and a greater benefit to patients. |
publishDate |
2019 |
dc.date.none.fl_str_mv |
2019-10-24 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigo de opnião |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/387 10.32635/2176-9745.RBC.2019v65n3.387 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/387 |
identifier_str_mv |
10.32635/2176-9745.RBC.2019v65n3.387 |
dc.language.iso.fl_str_mv |
por eng |
language |
por eng |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/387/478 https://rbc.inca.gov.br/index.php/revista/article/view/387/605 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2019 Revista Brasileira de Cancerologia info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2019 Revista Brasileira de Cancerologia |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 65 No. 3 (2019): July/Aug./Sept.; e-04387 Revista Brasileira de Cancerologia; Vol. 65 Núm. 3 (2019): jul./agosto/sept.; e-04387 Revista Brasileira de Cancerologia; v. 65 n. 3 (2019): jul./ago./set.; e-04387 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042243658317824 |